Literature DB >> 21203803

Expression and significance of HER family receptors in neuroblastic tumors.

Ewa Izycka-Swieszewska1, Agnieszka Wozniak, Elzbieta Drozynska, Jacek Kot, Wieslawa Grajkowska, Teresa Klepacka, Danuta Perek, Sylwia Koltan, Ewa Bien, Janusz Limon.   

Abstract

HER receptor family plays an important role in normal embryonic development and is involved in pathogenesis and progression of some types of cancer. Neuroblastic tumors (NT) are common pediatric neoplasms with a poor outcome in a significant number of patients. The biological and prognostic role of HER family in NT is not well established. In the current study we evaluated HER1-4 receptors expression, their prognostic significance and clinicopathological correlations in a series of 103 NTs by immunohistochemical assessment of HER1-4 expression and FISH analysis of EGFR and HER2 copy number status. HER receptors are commonly expressed in NT but it was not due to EGFR or HER2 amplification. EGFR, HER2 and HER4 show correlation with tumor histology. It seems that these receptors take part in neuroblastic cell differentiation and Schwannian stroma development. EGFR and HER2 positivity are more frequently found in favorable histological risk group of tumours (P = 0.004 and P = 0.01 respectively) while high expression of HER4 is significantly more often found in patients with metastatic disease (P = 0.03). Moreover tumors with HER2 polysomy were more often found in children ≤ 18 months, with localized disease, and favorable histological group. Our study showed that the role of HER family members in NT biology is interrelated and complex but their expression level may present a novel prognostic factor for NT patients outcome.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21203803     DOI: 10.1007/s10585-010-9369-1

Source DB:  PubMed          Journal:  Clin Exp Metastasis        ISSN: 0262-0898            Impact factor:   5.150


  37 in total

Review 1.  The diverse signaling network of EGFR, HER2, HER3 and HER4 tyrosine kinase receptors and the consequences for therapeutic approaches.

Authors:  A Zaczek; B Brandt; K P Bielawski
Journal:  Histol Histopathol       Date:  2005-07       Impact factor: 2.303

Review 2.  EGF-ERBB signalling: towards the systems level.

Authors:  Ami Citri; Yosef Yarden
Journal:  Nat Rev Mol Cell Biol       Date:  2006-07       Impact factor: 94.444

3.  Proliferation of human neuroblastomas mediated by the epidermal growth factor receptor.

Authors:  Ruth Ho; Jane E Minturn; Tomoro Hishiki; Huaqing Zhao; Qun Wang; Avital Cnaan; John Maris; Audrey E Evans; Garrett M Brodeur
Journal:  Cancer Res       Date:  2005-11-01       Impact factor: 12.701

Review 4.  ERBB2 in pediatric cancer: innocent until proven guilty.

Authors:  Richard J Gilbertson
Journal:  Oncologist       Date:  2005-08

5.  Expression of the HER1-4 family of receptor tyrosine kinases in breast cancer.

Authors:  Caroline J Witton; Jonathan R Reeves; James J Going; Timothy G Cooke; John M S Bartlett
Journal:  J Pathol       Date:  2003-07       Impact factor: 7.996

6.  High expression of HER3 is associated with a decreased survival in gastric cancer.

Authors:  Mikiko Hayashi; Mikito Inokuchi; Yoko Takagi; Hiroyuki Yamada; Kazuyuki Kojima; Jiro Kumagai; Tatsuyuki Kawano; Kenichi Sugihara
Journal:  Clin Cancer Res       Date:  2008-12-01       Impact factor: 12.531

7.  Induction of apoptosis by an inhibitor of EGFR in neuroblastoma cells.

Authors:  Shinichi Tamura; Hajime Hosoi; Yasumichi Kuwahara; Ken Kikuchi; Osamu Otabe; Moriatsu Izumi; Kunihiko Tsuchiya; Tomoko Iehara; Takahiro Gotoh; Tohru Sugimoto
Journal:  Biochem Biophys Res Commun       Date:  2007-04-27       Impact factor: 3.575

8.  Neural crest development and neuroblastoma: the genetic and biological link.

Authors:  Akira Nakagawara
Journal:  Prog Brain Res       Date:  2004       Impact factor: 2.453

9.  EGFR inhibition using gefitinib is not active in neuroblastoma cell lines.

Authors:  Jochen Rössler; Eva Odenthal; Birgit Geoerger; Aurore Gerstenmeyer; Jeanette Lagodny; Charlotte Marie Niemeyer; Gilles Vassal
Journal:  Anticancer Res       Date:  2009-04       Impact factor: 2.480

10.  Stratification of non-small cell lung cancer patients for therapy with epidermal growth factor receptor inhibitors: the EGFR fluorescence in situ hybridization assay.

Authors:  Marileila Varella-Garcia
Journal:  Diagn Pathol       Date:  2006-08-15       Impact factor: 2.644

View more
  9 in total

1.  Expression of acidosis-dependent genes in human cancer nests.

Authors:  Toshihiko Fukamachi; Shunsuke Ikeda; Hiromi Saito; Masatoshi Tagawa; Hiroshi Kobayashi
Journal:  Mol Clin Oncol       Date:  2014-07-11

2.  Slow down to stay alive: HER4 protects against cellular stress and confers chemoresistance in neuroblastoma.

Authors:  Yingqi Hua; Kirill Gorshkov; Yanwen Yang; Wenyi Wang; Nianxiang Zhang; Dennis P M Hughes
Journal:  Cancer       Date:  2012-03-13       Impact factor: 6.860

3.  Functional Common and Rare ERBB2 Germline Variants Cooperate in Familial and Sporadic Cancer Susceptibility.

Authors:  Riyue Bao; Anita Ng; Mark Sasaki; Myvizhi Esai Selvan; Alyna Katti; Hyesan Lee; Lei Huang; Andrew D Skol; Cinzia Lavarino; Hector Salvador; Robert J Klein; Zeynep H Gümüş; Jaume Mora; Kenan Onel
Journal:  Cancer Prev Res (Phila)       Date:  2021-01-08

4.  MYCN repression of Lifeguard/FAIM2 enhances neuroblastoma aggressiveness.

Authors:  L Planells-Ferrer; J Urresti; A Soriano; S Reix; D M Murphy; J C Ferreres; F Borràs; S Gallego; R L Stallings; R S Moubarak; M F Segura; J X Comella
Journal:  Cell Death Dis       Date:  2014-09-04       Impact factor: 8.469

5.  ERBB3 is a marker of a ganglioneuroblastoma/ganglioneuroma-like expression profile in neuroblastic tumours.

Authors:  Annica Wilzén; Cecilia Krona; Baldur Sveinbjörnsson; Erik Kristiansson; Daniel Dalevi; Ingrid Øra; Katleen De Preter; Raymond L Stallings; John Maris; Rogier Versteeg; Staffan Nilsson; Per Kogner; Frida Abel
Journal:  Mol Cancer       Date:  2013-07-08       Impact factor: 27.401

6.  ERBB3: A potential serum biomarker for early detection and therapeutic target for devil facial tumour 1 (DFT1).

Authors:  Dane A Hayes; Dale A Kunde; Robyn L Taylor; Stephen B Pyecroft; Sukhwinder Singh Sohal; Elizabeth T Snow
Journal:  PLoS One       Date:  2017-06-07       Impact factor: 3.240

7.  Regorafenib is effective against neuroblastoma in vitro and in vivo and inhibits the RAS/MAPK, PI3K/Akt/mTOR and Fos/Jun pathways.

Authors:  Divya Subramonian; Nikki Phanhthilath; Hannah Rinehardt; Sean Flynn; Yuchen Huo; Jing Zhang; Karen Messer; Qianxing Mo; Shixia Huang; Jacqueline Lesperance; Peter E Zage
Journal:  Br J Cancer       Date:  2020-05-27       Impact factor: 7.640

8.  Epithelial-mesenchymal transition-related gene expression as a new prognostic marker for neuroblastoma.

Authors:  Megumi Nozato; Setsuko Kaneko; Akira Nakagawara; Hiroaki Komuro
Journal:  Int J Oncol       Date:  2012-11-06       Impact factor: 5.650

9.  HER-2 Immunohistochemical Expression in Bone Sarcomas: A New Hope for Osteosarcoma Patients.

Authors:  Sahar A Tabak; Sara E Khalifa; Yasmine Fathy
Journal:  Open Access Maced J Med Sci       Date:  2018-09-04
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.